White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension

Cardiovascular Diseases, Heart Diseases, Hypertension

To investigate the mechanisms of white coat hypertension and study it further as a risk factor for heart damage.

BACKGROUND: The multidisciplinary SCOR examined causes, consequences, and treatments of human hypertension. A central theme was the renal basis for human hypertension. The subproject on white coat hypertension began in December of 1985. DESIGN NARRATIVE: In the longitudinal study, eighty patients with white coat hypertension were compared with 40 age- and sex-matched normotensives, and with 80 patients with sustained hypertension. The protocol consisted of (a) clinic blood pressure measurements made both by a physician and a nurse, (b) self-monitoring at home, (c) noninvasive ambulatory monitoring, (d) reactivity testing (cold pressor test, mental arithmetic, and isometric exercise) and (e) Korotkoff signal recording. Patients were also tested for early markers of disease (echocardiography and urine albumin). The 80 patients in each of the two hypertensive groups were randomized to one of four treatment protocols (20 patients each); an alpha blocker, a beta blocker, a combined alpha- and beta-blocker, or an ACE inhibitor. The doses of medication were adjusted to produce similar reductions of clinic blood pressure in the different groups. The test battery (a-e) was reported during treatment. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

No related papers found yet.

None listed